Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025 – Bristol Myers Squibb

Written by

admin

in

  1. Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025  Bristol Myers Squibb
  2. Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T  Business Wire
  3. Bristol Myers Squibb reports positive early results from CAR T therapy trial  Investing.com

Continue Reading

More posts